Invivyd reports Q2 net loss $50.2M; plans pivotal VYD222 trial for COVID-19 prevention

Invivyd, Inc.

2023-Q2 EPS reported -$0.78

Net loss of $50.2M ($0.46 per share) vs. $51.0M ($0.47) in Q2 2022; revenue none.
Cash & equivalents $298.4M; runway into Q4 2024, excluding potential product revenue.
Plans to initiate CANOPY pivotal trial of VYD222 (~750 participants) using Day 28 neutralizing titers as surrogate endpoint for EUA.
Phase 1 data showed favorable safety and robust neutralizing titers against Omicron XBB.1.5 at all three doses tested.
FDA alignment on immunobridging approach for EUA; expects initial CANOPY data by end of 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.4

Invivyd, Inc. reported financial results for quarter ended June 30, 2023.

Period: quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 10, 2023, Invivyd, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the quarter ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

Invivyd, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-209020

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.